-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Reiterates Buy on Tvardi Therapeutics, Maintains $9 Price Target

Benzinga·11/20/2026 11:24:02
HC Wainwright & Co. analyst Sara Nik reiterates Tvardi Therapeutics (NASDAQ:TVRD) with a Buy and maintains $9 price target.